Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (I)



I

~~and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which~~

wherein

R^1 and R^2 are independently selected from ~~represent~~ phenyl, thienyl ~~or~~ and pyridyl, each of which is independently optionally substituted ~~by~~ with one, two or three Z groups ~~represented by Z~~;

Z ~~represents~~ is selected from a C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl; ~~and~~

R^3 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, an aminoC_{1-3}alkyl group, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, ~~or~~ and ~~hydrazinocarbonyl of formula~~ –CONHNR^{a}R^b, wherein R^a and R^b are ~~as defined for~~ R^4 and R^5, respectively; and;

X is CO or SO_2;

Y is absent or ~~represents~~ NH, optionally substituted ~~by~~ with a C_{1-3}alkyl group;

R^4 and R^5 are independently ~~represent~~ selected from:

a C_{1-6}alkyl group;

an (amino)C_{1-4}alkyl– group in which the amino is optionally substituted ~~by~~ with one or more C_{1-3}alkyl groups;

an optionally substituted non-aromatic C_{3-15}carbocyclic group;

a (C_{3-12}cycloalkyl)C_{1-3}alkyl– group;

a ~~group~~ –$(CH_2)_r$(phenyl)$_s$ ~~in which~~ group, wherein r is 0, 1, 2, 3 or 4, and wherein s is 1 when r is 0, otherwise s is 1 or 2, and wherein the phenyl groups are optionally independently substituted ~~by~~ with one, two or three Z groups ~~represented by Z~~;

naphthyl;

anthracenyl;

a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen, wherein the heterocyclic group is optionally substituted ~~by~~ with one or more C_{1-3}alkyl groups, hydroxy or benzyl;

1-adamantylmethyl; and

a ~~group~~ –$(CH_2)_t$Het ~~in which~~ group, wherein t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted ~~by~~ with one or more C_{1-3}alkyl groups and wherein Het ~~represents~~ is an aromatic heterocycle optionally substituted ~~by~~ with one, two or three groups selected from a C_{1-5}alkyl group, a C_{1-5}alkoxy group ~~or~~ and halo;

or R^4 ~~represents~~ is H and R^5 is as defined above;

or R^4 and R^5 taken together with the nitrogen atom to which they are attached ~~represent~~ form a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted ~~by~~ with one or more C_{1-3}alkyl groups, hydroxy or benzyl;

R^6 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, ~~or~~ and ~~hydrazinocarbonyl of formula~~ –$CONHNR^aR^b$, wherein R^a and R^b are ~~as defined for~~ R^4 and R^5, respectively; and;

with the proviso that when R^6 is methyl, then the group X-Y-NR^4R^5 ~~does~~ is not ~~represent~~ $CONHC_6H_{13}$, $CONHC_{12}H_{25}$, $CONH_2$, $CONHCH_3$, $CON(CH_3)_2$,


or

;

and with the further proviso that when R^1 and R^2 are independently ~~represent~~ phenyl, then Z is not an ortho methyl group.~~;~~

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

2. (currently amended) A compound according to claim 1, ~~in which~~ wherein R^1 ~~represents~~ is phenyl optionally substituted in the 2 or 4 position ~~by~~ with halo or C_{1-3}alkoxy ~~located in the 2 and 4 positions of the phenyl ring~~.

3. (currently amended) A compound according to ~~any previous claim in which~~ claim 1, wherein R^2 is ~~represents~~ phenyl, optionally substituted in the 2 or 4 position ~~by~~ with halo or C_{1-3}alkoxy ~~located in the 2 and 4 positions of the phenyl ring~~.

4. (currently amended) A compound according to ~~any previous claim in which~~ claim 1, wherein X-Y-NR^4R^5 ~~represents~~ is CONHPh or CONH(1-piperidyl).

5. (currently amended) A compound according to ~~any previous claim in which~~ claim 1, wherein R^6 ~~represents~~ is methyl.

6. (currently amended) A compound according to claim 1 of the general formula (II) ~~in which~~



II

~~and pharmaceutically acceptable salts, prodrugs, and solvates in which~~

wherein

m is ~~represents~~ 0, 1, 2 or 3;

each R^7 ~~represents~~ is independently selected from a C_{1-6}alkyl group, trifluoromethyl, a C_{1-6}alkoxy group, difluoromethoxy, trifluoromethoxy, ~~or~~ and halo; ~~wherein when m is 2 or 3 then the groups R^1 may be the same or different;~~

n ~~represents~~ is 0,1, 2 or 3;

each R^8 ~~represents~~ is indepently selected from a C_{1-6}alkyl group, trifluoromethyl, a C_{1-6}alkoxy group, difluoromethoxy, trifluoromethoxy, ~~or~~ and halo; ~~wherein when n is 2 or 3 then the groups R^2 may be the same or different;~~

R^9 ~~represents~~ is selected from 1-piperidinyl, 1-piperidinylamino ~~or~~ and anilino, wherein the phenyl ring is optionally substituted ~~by~~ with one or more of the following: a C_{1-6}alkyl group, trifluoromethyl, a C_{1-6}alkoxy group, difluoromethoxy, trifluoromethoxy, or halo; and

R^{10} ~~represents~~ is selected from a C_{1-6}alkyl, C_{1-6}alkoxy, ~~or~~ and a C_{1-6}alkylamino group;

or a pharmaceutically acceptable salt, prodrug or solvate thereof;

with the proviso that the compound is not 1-{[1-(4-chlorophenyl)-5-phenyl-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine or 1-{[1-(2,4-dichlorophenyl)-5-phenyl-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine.

7. (currently amended) A compound according to claim 6, ~~in which~~ wherein m is 2 and ~~the groups~~ each R^7, if present, is ~~are~~ located in the 2 ~~and~~ or 4 ~~positions~~ position of the phenyl ring.

8. (currently amended) A compound according to claim 6, ~~or claim 7 in which~~ wherein n is 2 and ~~the groups~~ each R^8, if present, is ~~are~~ located in the 2 ~~and~~ or 4 ~~positions~~ position of the phenyl ring. ~~In a third group of compounds of formula II, R^9 represents anilino.~~

9. (currently amended) A compound according to ~~any one of claims~~ claim 6, ~~7 or 8 in which~~ wherein R^9 ~~represents~~ is 1-piperidinyl.

10. (currently amended) A compound according to ~~any one of claims~~ claim 6, ~~7, 8 or 9 in which~~ wherein R^9 ~~represents~~ is 1-piperidinylamino.

11. (currently amended) A compound according to ~~any one of claims~~ claim 6, ~~7, 8, 9 or 10 in which~~ wherein R^{10} ~~represents~~ is methyl.

12. (currently amended) A compound selected from ~~one or more of the following~~:

2-methyl-*N*,1,5-triphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-2-methyl-*N*,5-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-methoxyphenyl)-2-methyl-*N*,5-diphenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-2-methyl-*N*,1-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dimethoxyphenyl)-2-methyl-*N*,1-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

2-methyl-1,5-diphenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-2-methyl-5-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-methoxyphenyl)-2-methyl-5-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-{[5-(2,4-dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide; ~~and~~

5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-[(2-methyl-1,5-diphenyl-1*H*-pyrrol-3-yl)carbonyl]piperidine;

1-{[1-(4-methoxyphenyl)-2-methyl-5-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine; <u>and</u>

1-{[5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

and where applicable, optical isomers, tautomers, stereoisomers and racemates thereof as well as pharmaceutically acceptable salts and solvates thereof.

13. (cancelled)

14. (currently amended) A pharmaceutical ~~formulation~~ composition comprising a compound of ~~formula I, as defined in~~ any one of claims 1 to 12 and a pharmaceutically acceptable adjuvant, diluent or carrier.

15. (cancelled)

16. (currently amended) A method of treating a condition selected from obesity, psychiatric disorders, ~~such as~~ psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders, epilepsy, ~~and related conditions, and~~ neurological disorders, ~~such as~~ dementia, neurological disorders, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems, and extended abuse, addiction and/or relapse indications, in a mammal, comprising administering a pharmacologically effective amount of a compound ~~as claimed in of any one of claims 1 to 12 including the compounds of the proviso in claim 1~~ of formula (I)



I

wherein

R^1 and R^2 are independently selected from phenyl, thienyl and pyridyl, each of which is independently optionally substituted with one, two or three Z groups;

Z is selected from a C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

R^3 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, an aminoC_{1-3}alkyl group, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and $-CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively; and

X is CO or SO_2;

Y is absent or NH, optionally substituted with a C_{1-3}alkyl group;

R^4 and R^5 are independently selected from:

a C_{1-6}alkyl group;

an (amino)C_{1-4}alkyl– group in which the amino is optionally substituted with one or more C_{1-3}alkyl groups;

an optionally substituted non-aromatic C_{3-15}carbocyclic group;

a (C_{3-12}cycloalkyl)C_{1-3}alkyl– group;

a $-(CH_2)_r$(phenyl)$_s$ group, wherein r is 0, 1, 2, 3 or 4, and wherein s is 1 when r is 0, otherwise s is 1 or 2, and wherein the phenyl groups are optionally independently substituted with one, two or three Z groups;

naphthyl;

anthracenyl;

a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen, wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, hydroxy or benzyl;

1-adamantylmethyl; and

a $-(CH_2)_t$Het group, wherein t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted with one or more C_{1-3}alkyl groups and wherein Het is an aromatic heterocycle optionally substituted with one, two or three groups selected from a C_{1-5}alkyl group, a C_{1-5}alkoxy group and halo;

or R^4 is H and R^5 is as defined above;

or R^4 and R^5 taken together with the nitrogen atom to which they are attached form a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the

heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, hydroxy or benzyl; and

R^6 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and –$CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively;

to a patient in need thereof.

17. (canceled)

18. (currently amended) A process for the preparation of a compounds of claim 1 ~~formula I~~ in which X is CO,

comprising reacting a compound of formula III



III

in which R^1, R^2, R^3, and R^6 are as previously defined and wherein L is ~~represents~~ hydroxy or halo, with an amine of formula IV

$$R^4R^5YNH_2 \qquad IV$$

in which R^4 and R^5 are as previously defined, in an inert solvent and optionally in the presence of a catalyst or optionally in the presence of a base at a temperature in the range of -25°C to 150°C, and, when L is hydroxy, optionally in the presence of a coupling agent.

19. (currently amended) A compound of formula III



III

~~in which~~ wherein R^1, R^2, R^3, and R^6 are as ~~previously~~ defined in claim 1 and L ~~represents~~ is hydroxy or halo.

20. (currently amended) A compound selected from ~~one or more of the following~~:
Ethyl 2-methyl-1,5-diphenyl-1*H*-pyrrole-3-carboxylate,
Ethyl 1-(4-chlorophenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylate,
Ethyl 1-(4-methoxyphenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylate,
Ethyl 5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylate,
Ethyl 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,
Ethyl 5-(2,4-dichlorophenyl)- 1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,
Ethyl 5-(2,4-dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylate,
Ethyl 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,
Ethyl 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,
2-Methyl-1,5-diphenyl-1*H*-pyrrole-3-carboxylic acid,
1-(4-Chlorophenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylic acid,
5-(2,4-Dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylic acid,
1-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid,
5-(2,4-Dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid,
5-(2,4-Dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylic acid,
1-(4-Chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid, and
5-(2,4-Dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid.

21. (currently amended) ~~A compound as defined in any one of claims 1 to 12 combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of obesity such as~~ The composition according to claim 14,

comprising an additional agent useful in the treatment of hypertension, hyperlipidaemias, dyslipidaemias, diabetes or ~~and~~ atherosclerosis.